Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

103.40p
   
  • Change Today:
    -0.40p
  • 52 Week High: 110.00
  • 52 Week Low: 75.70
  • Currency: UK Pounds
  • Shares Issued: 538.04m
  • Volume: 210,571
  • Market Cap: £556.34m
  • RiskGrade: 119
  • Beta: 0.18

Strong trading continues in new year for Alliance Pharma

By Josh White

Date: Wednesday 19 May 2021

LONDON (ShareCast) - (Sharecast News) - Alliance Pharma updated the market on its trading on Wednesday, reiterating that the year had started well, adding that it was continuing to see some "strong performances" from its key brands.
The AIM-traded firm, which was holding its annual general meeting, said integration of the Biogix business and the Amberen brand into its US-based operations was progressing "very well", with integration almost complete.

Chairman David Cook said current trading and expectations for Amberen remained in line with its pre-acquisition forecasts.

"We remain confident in our ability to weather any ongoing disruption to our business in those areas of the world which continue to be challenged by the global pandemic, and to deliver full year results in line with market expectations," Cook said.

Alliance said further commentary on its first half trading performance and full-year outlook would be provided in mid-July, in its interim trading update.

At 1008 BST, shares in Alliance Pharma were up 0.29% at 95.28p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 103.40p
Change Today -0.40p
% Change -0.39 %
52 Week High 110.00
52 Week Low 75.70
Volume 210,571
Shares Issued 538.04m
Market Cap £556.34m
Beta 0.18
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
86.45% below the market average86.45% below the market average86.45% below the market average86.45% below the market average86.45% below the market average
12.00% above the sector average12.00% above the sector average12.00% above the sector average12.00% above the sector average12.00% above the sector average
Price Trend
60.29% above the market average60.29% above the market average60.29% above the market average60.29% above the market average60.29% above the market average
40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average
Income
50.29% below the market average50.29% below the market average50.29% below the market average50.29% below the market average50.29% below the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average
Growth
13.58% below the market average13.58% below the market average13.58% below the market average13.58% below the market average13.58% below the market average
94.12% below the sector average94.12% below the sector average94.12% below the sector average94.12% below the sector average94.12% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 3
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Interim Final
Ex-Div 16-Dec-21 10-Jun-21
Paid 07-Jan-22 08-Jul-21
Amount 0.56p 1.07p

Trades for 08-Dec-2021

Time Volume / Share Price
12:31 715 @ 103.40p
12:29 2,037 @ 103.66p
12:28 14,952 @ 104.00p
12:23 10,000 @ 103.99p
12:01 483 @ 104.00p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin

Top of Page